HOME >> BIOLOGY >> NEWS
Finding a cellular Neverland: How stem cells stay childlike

La Jolla, CA - Despite their celebrated "immortality," the capacity of embryonic stem (ES) cells for endless division has its limits. After a very extended childhood spent dividing in a culture dish, even stem cells tend to grow up and assume adult roles as workaday nerve, muscle, or blood cells, never to return to their youthful state.

How some ES cells succeed in recapturing lost cellular innocence and start anew once they begin maturing is described in a forthcoming study in Proceedings of the National Academy of Sciences, authored by a team of scientists from the Salk Institute for Biological Studies.

The team, headed by professor Juan Carlos Ispiza Belmonte, Ph.D., of the Gene Expression Laboratory and including professor Fred Gage, Ph.D., of the Laboratory of Genetics, demonstrates how a DNA-binding protein called Nanog coaxes mouse ES cells trying to differentiate into muscle cells back into an immature state. Nanog is named for the legendary Celtic land Tir nan Og where people remained forever young

"Embryonic stem cells represent enormous hope for treating otherwise incurable diseases," says Belmonte. "But before we can design therapeutic strategies or introduce these cells into patients, we must learn how to differentiate them into specific cell types and how to tame their formidable proliferating ability," he explains.

Nanog is a critical factor required for what cell biologists call "stemness," which is defined by two qualities: the ability of ES cells to divide or "self-renew" and their plasticity in assuming the identity of almost any cell type, which is also known as "pluripotency."

In a study published earlier this year, the same Belmonte and Gage lab team demonstrated that a few ES cells in a culture dish tended to lose stemness and evolve into muscle cell precursors, most likely goaded by a muscle differentiation factor known as BMP. But when those maturing cells were forced to produce Nanog, they re
'"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-4100 x1340
Salk Institute
26-Jun-2006


Page: 1 2 3

Related biology news :

1. Finding protection from tumor growth in unexpected places
2. Finding the white wine difference
3. Finding an answer to Darwins Dilemma
4. Finding a cure for cancer: The holy grail of science
5. Finding the right mix: A biomaterial blend library
6. Finding paves way for better treatment of autoimmune disease
7. Finding about cellular microtubule rigidity could lead to development of new nano-materials
8. Findings by Einstein scientists reveal possible strategy against obesity, diabetes and infertility
9. Finding of a new molecular marker of resistance to chemotherapy in breast cancer
10. Finding a virus is not all bad news
11. Finding life on Mars and outer space begins by examining Earths inner space

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Finding cellular Neverland How stem cells stay childlike

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: